BMS-986278, a second-generation LPA 1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD. Methods and analysis This phase 2, randomised, double-blind, placebo-controlled, parallel-group, international trial will include adults with IPF or PF-ILD. The trial will...
BMS-986278 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in...See More Phase 3 View trial Save trial Hematology Acute Myeloid Leukemia Trial Title Phase BMS-986397 Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Parti...See More ...